Our sister site, Drug Delivery Business News, reports today that the FDA cleared the removal of the imaging contradiction for the FreeStyle Libre 2 and 3 continuous glucose monitors (CGMs) for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings.
Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor, too.
Get the full story at our sister site, Drug Delivery Business News.
